Abstract 528P
Background
Precision medicine has been increasingly practiced to select best-fit systemic treatment for advanced and metastatic (a/m) NSCLC. Though new treatment options help improve survival outcomes, they have led to increased financial burdens. In Hong Kong, limited financial assistance programs place the majority of treatment cost on patients. Our study aims to identify gaps in accessing standard-of-care (SOC) treatments and its determinants.
Methods
This prospective, territory-wide cohort study enrolled newly diagnosed a/m NSCLC patients from seven public oncology centers in Hong Kong since Mar 2021. Data on genomic landscape, treatment patterns and socioeconomic status (SES) of NSCLC patients were collected. Provision of SES data was voluntary. Patients were dichotomized into with or without druggable mutations. Proportion of patients receiving SOC were reported and analyzed in relation with SES parameters.
Results
Among 350 patients with SES data, 194 (55.5%) paid out-of-pocket costs for treatments, 110 (31.5%) were partially reimbursed by means-tested subsidy and 34 (9.7%) were fully reimbursed in employee remuneration package. Household income (HI) of 215 patients (60.9%) is less than 23000 USD/year, 95 (26.9%) between 23001-55300 USD/year, and 43 (12.1%) above 55301 USD/year. About 50% of patients had at least 2 children, lived with family members and received secondary education or above. For patients with druggable mutation (n=259), 152 (58.7%) received corresponding targeted treatments. In multivariate analyses (MVA), patients with HI >= 23001 USD/yr is significantly more likely to follow SOC than those with lower income. Self-financed patients are significantly more likely to receive targeted therapies than those with subsidy (OR: 3.73, p=0.004). For patients without druggable mutation (n=77), 32 (52%) received immunotherapy alone or combination. In MVA, patients with HI above 55301 USD/year are more likely to receive immunotherapy as part of treatment than those with lower income (OR: 11.90, p=0.08).
Conclusions
Patients with HI below 55301 USD/year is at risk of deprivation to accessing SOC treatment. Societal efforts are needed to secure equitable access to cancer treatment to all.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Hong Kong.
Funding
Innovation and Technology Commission (HKSAR) & Roche.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract